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Abstract. Evidence-based medicine requires that medical decisions are taken based
on available, verified and high quality evidence, in particular in the form of ran-
domized clinical trials (RCTs). Such evidence is mainly obtained from multiple rel-
evant published studies and synthesized in systematic reviews and meta-analyses.
Therefore, aggregating and summarizing the level of evidence across different clin-
ical studies are relevant tasks in the medical context. Towards the development of
a system that aggregates, compares and rationalizes upon the evidence from mul-
tiple clinical trials, we developed an ontology that models such studies. The ontol-
ogy considers clinical trial elements as well as other pieces of evidence and their
relationships, which support the aggregation and rationalization of the level of ev-
idence across studies. On the basis of this conceptualization of clinical trials, we
also obtained a knowledge base for the extraction of evidence via SPARQL queries,
and an annotation scheme for annotating clinical trial publications. We validated
our ontology through a case study on glaucoma, in which the ontology proved to be
able to answer the competency questions required for aggregating and rationalizing
the results across different studies.
Keywords. ontology, clinical trials, knowledge base, evidence aggregation, evidence-
based medicine
1. Introduction
In paradigms that do not consider evidence (e.g., eminence-based medicine) there may
exist a risk of bias caused by the lack of a robust statistical analysis, conflict of interest,
or decisions made based on personal experience only. In order to avoid this risk, the
current paradigm for medical decision making requires evidence-based reasoning [1,2].
Thus, decisions should be made based on available, verified and high quality evidence.
Such evidence is typically obtained from randomized clinical trials (RCTs), which are
considered as the gold-standard for clinical research.
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(CITEC), Bielefeld University, Inspiration 1, 33619 Bielefeld, Germany; E-mail: olivia.sanchez@uni-
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In order to decide which treatment could be comparatively more effective in terms
of efficacy and safety relying on high quality evidence, it is necessary to collect evidence
from multiple relevant studies, whilst considering the possible presence of bias and the
shortcomings of those studies. Therefore, clinicians need to synthesize and compare the
aggregated information, which is normally done in the form of systematic reviews and
meta-analyses. These meta-studies and reviews try to consider all the evidence contained
in multiple controlled clinical studies and related publications available in open-access
databases such as PubMed2. However, reviewing the vast number of publications re-
quires an extensive manual effort. Besides the fact that this effort is costly in terms of
time and money, the corresponding reviews are typically outdated at the time of publica-
tion. For these reasons, there is a great interest in automatizing the generation of system-
atic reviews [3,4,5,6]. This automatization requires to capture the outcomes and values
of multiple studies formally in a machine-interpretable way. Furthermore, when formal-
izing the results from clinical studies to support cross-study aggregation, it is necessary
to consider several aspects, such as the use of different terminologies, different units, in-
complete information, different ways of reporting results, etc. Therefore, ontologies that
are able to represent the characteristics and results of clinical studies on a semantic level,
abstracting from the original publication and such that comparison and aggregation of
evidence is supported, are needed.
With the aim to support the automatization of systematic reviews and meta-analyses,
which implies the aggregation, comparison and rationalization of the level of evidence
from multiple clinical trials, we present the clinical trial ontology (C-TrO) which models
not only the PICO3 elements, but also other relevant pieces of evidence that are necessary
for carrying out these tasks.
The remainder of this paper is structured as follows: Section 2 describes the design
and development of C-TrO, whilst Section 3 describes its structure. The validation of C-
TrO through a case study is provided in Section 4. An example of the use of C-TrO in the
annotation of text is given in Section 5. Section 6 offers final remarks and conclusions.
2. Ontology Design and Conceptualization
In order to establish the requirements and the suitable development methodology for
our ontology, we first describe the objectives of C-TrO. Afterwards, we describe the
corresponding methodological aspects.
2.1. Uses and Requirements of the Ontology
The main goals of our ontology are: 1) provide the structure for a knowledge base that
stores the information obtained from published clinical trials and other related informa-
tion sources; 2) provide the logical structure from which it is possible to summarize and
aggregate the level of evidence from multiple trials through SPARQL queries; and 3)
support an annotation scheme of concepts and their relationships in clinical trial publi-
cations. The manually annotated corpus will be used for training/testing an IE system
2https://www.ncbi.nlm.nih.gov/pubmed
3PICO stands for P: population or patients and problem, I: intervention, C: comparison and O: outcome.
that will extract the concepts and relations from clinical trial abstracts and automatically
populate the knowledge base with this information.
Consequently, C-TrO is meant to describe any type of clinical trial for any health
condition, and to take into account important information such as risk of bias, results
according to a given aggregation method, relative or absolute risks, size of effect, and any
other information that could support rationalized decision-making as to which medical
treatments are comparatively more efficacious or/and safer than others.
Besides considering the PICO framework, which describes the basic information
structure of clinical trials, the structure of the ontology must facilitate the comparison of
different interventions across multiple studies by considering clinical arms as interven-
tion groups. We shortly review the PICO elements as follows.
2.1.1. PICO Elements
Clinical arms are groups of patients (or any other unit of study) that receive one or more
clinical interventions according to a given protocol. Population refers to the participants
in the clinical trials who have a certain health condition and receive the medical interven-
tions. An intervention is a medical treatment applied to a group of participants with the
aim to combat diseases or other health disorders. Comparison refers to the comparison
between two interventions, in which usually one of them serves as control (e.g. placebo).
Outcomes are the results of the analysis relative to the measures obtained after the inter-
vention(s) applied to an arm (e.g. statistical analysis and size of effect calculations) for
the given outcome indicators (or endpoints), i.e., variables that pertain to the clinical trial
objective. Outcomes can be primary or secondary outcomes. Primary outcomes refer to
the most relevant endpoints that are expected to change as the result of the application of
the intervention(s). While secondary outcomes are used for evaluating additional effects.
2.2. Methodology
Our ontology has to comply with both software engineering and text annotation aspects,
as well as to serve as a basis for storing evidence from multiple clinical studies in a
knowledge base. This information should be efficiently stored and retrieved. Thus, the
information should be structured and logical, but also intuitive and coherent for the users
(both annotators and clinicians). Consequently, the expressivity of the ontology should
not have a high level of complexity and inference and should allow an efficient access to
the information. Therefore, we decided to employ the macro-level development method-
ology On-ToKnowledge [7], which consists of five phases: feasibility study, kickoff, re-
finement, evaluation and application, and evolution. Unlike other methodologies, On-
ToKnowledge is suitable for our work, since it considers the iterative refinement and
evaluation of the ontology, which allows to obtain a most complete ontology structure.
Besides, the development is driven by other processes that consider both software engi-
neering and human aspects.
The specification of the ontology requirements of the kickoff phase includes the
description of what the ontology should be competent to answer, the identification of
relevant knowledge sources for the ontology description, the definition of concepts and
relations, the hierarchical structure of the ontology, and the consideration of existing
ontologies to be reused.
The competency questions specified in the kickoff phase are used along the devel-
opment of the ontology as well as in the evaluation and refinement phases.
The ontology was implemented with Protégé V. 5.2.0 4 and was validated by execut-
ing queries on the knowledge base that answer the corresponding competency questions
for a case study on glaucoma.
2.2.1. Knowledge Sources
In order to design the ontology, we analyzed abstracts and full articles that describe clin-
ical trials and meta-analyses of different diseases and health conditions. More specifi-
cally, we concentrate on glaucoma and type 2 diabetes mellitus. We analyzed 40 abstracts
of the glaucoma corpus [8] and 40 abstracts of diabetes and a pair of meta-analysis in
glaucoma obtained with the PICO linguist tool5. Three systematic reviews on diabetes
were provided by a medical practitioner expert in that field. It is possible to generalize
to other diseases since the abstracts follow similar formats to report the trials and their
results.
On the basis of the analysis of these publications, we identified and conceptualized
the main entities mentioned in the studies together with their respective relationships.
For example, we observed that an arm can have one or more interventions and that an in-
tervention can have more than one medication or a combination of medications, or other
types of therapies (e.g. psychotherapy). The assessment of the quality of the evidence
was analyzed following the GRADE [9,10] criteria6.
2.2.2. Competency Questions
Competency questions are of great importance for defining the scope of the conceptu-
alization of the ontology [11]. They also help in the iterative evaluation of the ontology
in the different development phases. The competency questions that our ontology should
be able to answer are related to the aggregation of the available evidence across multiple
clinical trials to determine superiority of the interventions.
We agreed upon the critical questions based on basic reasoning patterns for superior-
ity (in terms of efficacy and safety) of the interventions that were derived from our anal-
ysis. In such patterns a set of premises yield to a conclusion. For example, in a reasoning
pattern for superiority on efficacy, a major premise expresses the general objective of
the primary outcome of the intervention, and a minor premise considers the magnitude
of the differences between the intervention results. We also considered questions that
would challenge the conclusion in the reasoning patterns. For example, questions about
the statistical significance of the results, or the size of the population that receives the
intervention. Some of the specified competency questions are the following:
CQ1 Which studies report that the intervention using drug1 is more effective than the
one using drug2 in reducing (increasing) a given outcome indicator for a certain
disease?
CQ2 In which studies, is the reduction (increment) of the output indicator statistically
significant?
4https://protege.stanford.edu/
5https://babelmesh.nlm.nih.gov/pico.php
6http://www.gradeworkinggroup.org/
CQ3 In how many studies was it observed that a given drug intervention produced a
given adverse effect?
CQ4 How reliable is the evidence from these studies on basis of their risk of bias or
trial design?
Further competency questions can be formulated by combining the different ele-
ments of the ontology according to the preferences of the expert users. For example,
the first competency question can become more specific if we add population’s country,
gender, age range and ethnicity. Thus, the resulting question would turn into:
“Which studies report that the intervention using drug1 is more effective than
the one using drug2 in reducing (increasing) a given outcome indicator for a
certain disease in a population that resides in a certain country, composed by
only men (women) with ages between x and z and a given ethnicity?”
2.3. Related Ontologies
The RCT Schema ontology [12], which was developed in an Ocelot frame-based for-
mat7, models different phases of the clinical trial life cycle (e.g., trial design, protocol
management and protocol execution). This ontology has a very comprehensive structure
for capturing clinical trial information. However, it does not include some relevant prop-
erties for determining intervention superiority, such as the “direction of the outcome”
which indicates whether the final value is a reduction or an increment from the baseline.
This is an important information for the training of our IE system, since in published
clinical trials it is uncommon that the baseline value is reported. Instead, it is mentioned
whether the final value is a reduction or an increment from the baseline.
The Cochrane PICO ontology [13] is used for the annotation of three types of PICO
models identified in the Cochrane8 reviews. These annotations are meant to support the
formulation of questions and search of clinical trials. This ontology does not include a
more fine-grained information such as the frequency and interval of the treatments or the
risk of bias and the quality of the evidence.
The OCRe ontology (Ontology of Clinical Research) [14,15] is a formal model that
uses the OWL2 language to represent the different phases of clinical research, like the
study design, the execution, and the interpretation of data. OCRe focuses on the abstract
description of the studies rather than the quantitative representation of the results of the
respective clinical studies.
The above mentioned ontologies have different granularity of representation. How-
ever, a higher level of detail would be needed in some aspects in order to compare the
results of different studies and aggregate them into a coherent summary of the level of
evidence. Table 1 presents a comparison of the characteristics useful for supporting the
aggregation of the level of evidence of the described ontologies and C-TrO. It can be
observed that C-TrO shares some similarities with the other ontologies, in particular with
aspects of the PICO ontology that are concerned with the respective PICO elements.
7Frames are equivalent to classes and slots to attributes.
8The Cochrane Foundation: https://www.cochrane.org/
Table 1. Comparison of characteristics of clinical trial ontologies useful for supporting the aggregation of the
level of evidence.
Ontology /
Characteristics
RCT Schema PICO Ontology OCRe C-TrO
Main use Preparation of
reports and
analysis of RCTs.
Annotation of
Cochrane Reviews
according to its
PICO models.
Indexing of
research data
across different
clinical data
resources.
Knowledge base
and annotation
schema for the
aggregation and
rationalization of
the level of
evidence of
clinical trials.
Considered
PICO elements
(classes)
AnalyzedPopulation,
Intervention-Arm:
allows multiple
interventions per
arm, Outcome:
different types of
outcomes,
including
Side-effects.
InterventionGroup
(arm),
Interventions and
Outcomes related
through
PICO Comparison:
only descriptive
results.
AdverseEffect
class.
ArmPopulation,
InterventionStudy
Protocol: is
divided into Arms
(and Epocs),
Outcome: is an
analysis
specification.
Adverse effects
are not modeled.
Arms are related
to Population and
allow multiple
Interventions,
which can have
different
Outcomes
(primary,
secondary and
adverse effects).
Level of
granularity
Detailed.
However, the
object properties
are not clear.
Detailed.
However, the
outcome results
are descriptive
rather than
numeric values.
Very-detailed.
However, the
outcome results
are descriptive
rather than
numeric values.
Detailed. It
includes numeric
values for
outcome results in
different formats:
absolute, relative
or countable
values.
DL expressivity
(in Protégé)
Not specified ALCO(D)a ALCROIQ(D) ALCOF(D)
Considered risk
of bias/evidence
quality aspects
Some aspects: in
Trial-Details (e.g.
fraud and stopping
details).
No No Yes, in
EvidenceQuality
(e.g. GRADE rate,
conflict of
interest, etc.)
Availability pont formatb.
Restricted access
to the formalized
clinical trials.
Turtle format (ttl).
Restricted access
to the ontology.
Open access to the
schema. No
formalization of
clinical trials is
available.
Open access to the
schema. The
formalization of
clinical trials is in
progress.
a Aproximate expressivity considering the ontology scheme at https://linkeddata.cochrane.org/pico-ontology
b http://rctbank.ucsf.edu/home/trialreporting/rct-schema-1
2.4. Alignment with Other Ontologies
Even though the current version of C-TrO does not integrate any external ontology, C-
TrO allows the alignment of relevant medical ontologies, (e.g. SNOMED9) for diseases
9https://www.nlm.nih.gov/healthit/snomedct/index.html
or health conditions and drugs. Other terminologies or classification models could also
be integrated, such as the International Code for Diseases ICD-1110 or the Anatomical
Therapeutic Chemical (ATC) Classification System11. At the moment, the respective dis-
ease and drug Ids are added during the knowledge base curation phase since these iden-
tifiers are not included in the published studies. In future work, we will consider cross-
linking C-TrO to the Evidence and Conclusion Ontology (ECO)12 in which evidence is
established as a type of information that supports an assertion (a statement about some-
thing). Such a procedure would be compatible with our work on reasoning patterns for
superiority of interventions, in the sense that the conclusions would be equivalent to the
ECO assertions and the premises would be similar to the ECO supporting evidence for
the assertions.
3. Description of the Ontology Structure
In this section we describe the main classes and relations of C-TrO, whose structure is
depicted in Figure 1.
Figure 1. Diagram of the main classes of C-TrO: Data properties are in blue and Object properties in black.
The arrows start in the domain classes and end in the range classes.
A clinical trial is described in terms of its objective, the number of patients involved,
its duration, and its conclusion. A clinical trial analyses health conditions such as dis-
eases, disorders, or syndromes and has a desired outcome that is an endpoint described
in terms of a desired value for each measurement. The clinical trial is related to a certain
population with attributes such as gender, ethnicity, country of residence, minimum age,
10https://www.who.int/classifications/icd/en/
11https://www.whocc.no/atc ddd index/
12http://evidenceontology.org/
maximum age, and description of preconditions. A clinical trial has a number of arms
(Intervention groups). Each arm has a given number of patients who receive one or more
interventions. Each arm defines one or more interventions such as the administration of
a medication in a certain dose with a certain delivery method13. Arms have outcomes
that can be primary or secondary. Outcomes are specified in terms of an analysis met-
ric, baseline value, time points, measurement devices, and an ideal (desired) value of
the outcome. An outcome has an endpoint, which is an outcome indicator with an ag-
gregation method, measurement unit, a desired effect direction (e.g., whether a measure
should be decreased by the intervention), and the final number of patients. Outcomes
have results which can be qualitative or quantitative (e.g. absolute values, relative val-
ues and countable values), and the direction of the result (i.e., reduction or increment).
Arms (Intervention groups) also have adverse effects, which are reported qualitatively or
quantitatively in the results. Results have statistical measurements that include p-value
for a given type of statistical test, a confidence interval, a standard deviation, a standard
error, etc. Furthermore, the outcome can be described in terms of its effect size, which is
in turn described in terms of an effect size method and value. A publication is described
with publication meta-data and links to the clinical trial that it presents. A clinical trial
may present Evidence Quality indicators, such as risk of bias, to be pharmacy sponsored,
or to have a GRADE rate.
3.1. Completeness
Whilst C-TrO does cover the main aspects for modeling clinical trials and for rationaliz-
ing recommendation (i.e. those aspects relative to the PICO elements and the quantitative
results of the interventions), its structure will remain open to modifications in order to be
able to account for new methodologies, diseases and drugs or any other kind of emerging
evidence.
Regarding the completeness of the information in the knowledge base, the fact that
abstracts follow a similar reporting structure that the one proposed by the CONSORT
standards14 (e.g. title, authors, trial design, methods, results, conclusions, trial registra-
tion and funding), facilitates the identification of several important evidential informa-
tion in clinical trial abstracts. However, it is important to mention that some information
may not be included in the abstracts. For instance, information that denotes quality indi-
cators, such as conflict of interest (e.g.“The author(s) have no proprietary or commercial
interest”) and funding is rarely reported.
3.2. Upper Ontology
C-TrO does currently not rely on an upper ontology. However, in order to improve the
interoperability, open use, and collaborative development of C-TrO, we will consider
using an upper-ontology such as the Basic Formal Ontology (BFO)15, which is part of the
Open Biological and Biomedical Ontology (OBO) Foundry collection16. In this respect,
further work towards the creation of adequate mappings will be necessary.
13Interventions are not restricted to drug medications. They could be of other types (e.g. physiotherapies)
that could be added to C-TrO.
14http://www.consort-statement.org/
15http://basic-formal-ontology.org/
16http://obofoundry.org/
4. Case Study on Glaucoma
In order to validate the ability of C-TrO to answer the required competency questions, we
decided to focus on the health condition “glaucoma”, which has previously been studied
by other evidence mining approaches [8,16] and which involves a clear primary outcome.
Glaucoma is a disease that damages the optic nerve and that can lead to permanent visual
loss. The damage of the optic nerve usually occurs when the internal pressure in the eye
(IOP) increases17. Therefore, the reduction of IOP is a desired outcome in an intervention
for glaucoma.
For this case study, we consider the RCTs compared in the meta-analysis carried out
by Zhang et al. [17], in which two widely used drugs for treating glaucoma, latanoprost
and timolol, are compared. The aim of the meta-analysis was to evaluate and compare
the efficacy and the tolerance (or safety) of the two drugs. The quality of the evidence
was assessed by considering the design characteristics of the clinical trials such as mask-
ing, randomization, etc. The main outcome measures studied were the percentage of IOP
reduction for efficacy, and the relative risk for side effects (e.g. hyperaemia, conjunctivi-
tis, etc.). The meta-analysis suggested that latanoprost was more effective than timolol in
lowering IOP. However, it was observed that latanoprost often caused iris pigmentation.
It was also found that latanoprost once daily evening regime was superior compared to
latanoprost once daily morning regime.
We formalized these clinical trials in the knowledge base derived from C-TrO, which
is encoded in RDF triples. Figure 3 in Appendix A shows an example of the RDF triples
corresponding to a clinical trial on glaucoma, one of its arms and one of the arm’s inter-
ventions.18
4.1. Answering Competency Questions
We used SPARQL19 queries to retrieve information from the knowledge base for answer-
ing the corresponding competency questions. The competency question CQ1 has been
reformulated for our case study on glaucoma as:
“Which studies report that the intervention using latanoprost is more effective than
the timolol treatment in reducing the diurnal mean IOP for glaucoma?”
The answer to this question is shown in Table 2 and the corresponding SPARQL
query is presented in Appendix B.1. The average mean for latanorpost treatments is 7.3
mmHg and for timolol treatments 5.65 mmHg.
The retrieved information shows that in eleven comparable clinical trials, the la-
tanoprost treatment reduced the diurnal mean IOP from the baseline in greater magni-
tude than the timolol treatment. This suggests that under the given circumstances20, the
latanoprost treatment is more effective compared to the timolol treatment in reducing the
diurnal mean IOP.
17For more details about glaucoma visit https://www.glaucoma.org
18The formalized clinical trials used in this case study are available at: http://scdemo.techfak.uni-
bielefeld.de/clintrials/clintrials.owl
19https://www.w3.org/TR/rdf-sparql-query/ C-TrO to an upper-ontology
20These circumstances can be changed by retrieving other information from C-TrO as required (e.g. dose,
frequency, interval, etc.)
Table 2. Answer to the competency question CQ1 relative to the reduction of diurnal mean IOP (CT n is the
clinical trial identifier).
CT Id Reference Mean IOP reduction by Mean IOP reduction
Latanoprost (mmHg) by Timolol (mmHg)
CT 1 Alm A et al,1995 7.8 6.7
CT 1 Alm A et al,1995 8.6 6.7
CT 10 Nicolela MT et al.,1996 6.8 5.3
CT 11 Drance SM et al.,1998 3.6 3.1
CT 2 Aquino MV et al.,1999 11.1 9.1
CT 3 Camras CB et al.,1996 6.7 4.9
CT 4 Diestelhorst M et al.,1998 4.9 2.1
CT 5 Mastropasqua L et al,1999 4.8 4.6
CT 6 Mishima HK et al.,1996 6.2 4.4
CT 7 Rulo AH et al.,1994 8.9 5.9
CT 8 Watson P et al,1996 8.5 8.3
CT 9 Diestelhorst M et al.,1997 9.8 6.7
Average Mean 7.3 5.7
Table 3 shows the answer to the competency question CQ2 reformulated for the case
of glaucoma as:
“In which studies is the diurnal mean IOP statistically significant?”.
Only those p-values that were reported in the clinical studies are retrieved. In our
example, only four studies reported the p-values of the respective interventions. The
corresponding SPARQL query is shown in Appendix B.2.
Table 3. Answer to the competency question CQ2 relative to the statistical significance (p-values) of the
reduction of diurnal mean IOP.
CT Id Latanoprost intervention p-value Timolol intervention p-value
CT 2 CT2 Intervention1 < 0.001 CT2 Intervention2 < 0.001
CT 3 CT3 Intervention1 < 0.001 CT3 Intervention2 < 0.001
CT 5 CT5 Intervention1 < 0.001 CT5 Intervention2 < 0.001
CT 9 CT9 Intervention1 < 0.001 CT9 Intervention2 < 0.001
5. Example of the Use of C-TrO for Text Annotation
As mentioned before, one of the purposes of C-TrO is to guide the annotation of the
evidence found in clinical trial publications in order to create a training corpus for an IE
system. Therefore, hundred of abstracts of clinical studies will be manually annotated
to form such corpus. Once the IE system is trained, it will automatically extract similar
information (i.e., C-TrO concepts and relations) and populate the knowledge base with
this information. Figure 2 shows an example of an abstract annotated with the SANTO
annotation tool [18] that can be configured to follow the C-TrO structure. Thus, single
annotated entities can be grouped into predefined slots (i.e. class instances) according to
the C-TrO classes. The annotated text can be saved in an RDF format that formalizes
the annotated entities and their relationships (i.e. data properties and object properties),
and in an annotation format that contains the span positions of the individual entities and
indicates to which composed entities (i.e. instances) they belong. Figure 4 in Appendix C
shows the annotation of group Publication 1 (i.e., an instance of Publication) in an “an-
notated format” file and in the corresponding RDF file it is indicated that Publication 1
describes ClinicalTrial 1 (i.e., an instance of ClinicalTrial).
Figure 2. Example of the annotation of a clinical trial with the SANTO tool (The numbers on the left side of
the text indicate the sentence number).
6. Conclusions
We have presented C-TrO, an ontology for modeling clinical trial information for the
aggregation and rationalization of evidence. The development of C-TrO considered both
human and system development aspects. Some concepts and relationships of C-TrO are
similar to the ones of existing ontologies for clinical studies. However, C-TrO has a more
detailed level of representational granularity in order to aggregate and rationalize the ev-
idential information from multiple studies. We have shown that C-TrO is able to answer
competency questions related to the aggregation of evidence to determine and rationalize
the superiority of interventions in terms of efficacy and safety. In future work, we plan
to continue using C-TrO for guiding the annotation of clinical trials abstracts. The set of
annotated abstracts will form a training corpus for an IE system that identifies pieces of
evidence and the relationships between them. We intend to improve the interoperability
of C-TrO by means of an upper ontology. In due course, we expect C-TrO to constitute
the backbone of a system that aggregates and summarizes the level of evidence from clin-
ical trials, and that generates clinical recommendations. Our ontology, knowledge base
and annotated corpus will be provided as open-access resources.
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Appendix A Knowledge Base
:CT_3 rdf:type ctro:ClinicalTrial ;
:hasObjectiveDescription "Latanoprost, a new prostaglandin..." ;
:hasConclusionComment "Latanoprost has the potential..." ;
:hasAnalysisApproach PreProtocol ; :hasArm Arm_31, Arm_32 ;
:hasPopulation :CT3_Population ; :hasCTDesign :DoubleBlind, :Randomized .
:Arm_31 rdf:type ctro:Arm ;
:hasNumberPatients 134 ; :hasIntervention :CT3_Intervention1 .
:hasPrimaryOutcome :CT3_A1_OC1 ; :hasAdverseEffect :CT3_A1_AE1 ;
:CT3_Population rdf:type ctro:Population ;
:hasPreconditionDescription "Ocular hypertension and glaucoma" .
:hasMinAge 30 ; :hasMaxAge 90 ;
:hasCountry :USA ; :hasGender "Mixed" ;
:CT3_Intervention1 rdf:type ctro:Intervention ;
:hasFrequency "Once_at_evening";
:hasInterval "Daily" ; :hasDuration "3 months";
:hasAnalysisMetric "ChangeFromBaseLine" ;
:hasDesiredEffectDirection "Reduction"; :hasMedication :CT3_I1_M1 .
:CT3_A1_OC1 rdf:type ctro:Outcome ;
:hasEndpoint :EndPoint_CT3_A1_OC1 ;
:hasAggregationMethod "Mean" ;
:hasBaselineValue 25.3 ; :hasBioAndMedUnit :mmHg ;
:hasResult :Result_CT3_I1_OC3 .
:EndPoint_CT3_A1_OC3 rdf:type ctro:EndPoint ;
:hasEndpoint Description :Diurnal_IOP .
:Result_CT3_I1_OC3 rdf:type ctro:Result ;
:hasResultValue 6.7 .
:CT3_I1_M1 rdf:type ctro:Medication;
:hasDrug :Timolol; :hasDoseValue 005;
:hasBioAndMedUnit "Percent"; :hasDeliveryMethod "Eyedrops".
Figure 3. Excerpt of an RDF representation of a clinical trial from C-TrO (Note: A dose of 0.005% timolol
solution corresponds to one eyedrop.)
Appendix B SPARQL Queries
B.1 Query for Retrieving the IOP Mean Reduction
The following query retrieves pairwise comparisons of the diurnal IOP reduction values
from baseline of the interventions in each clinical trial in the case study on glaucoma.
SELECT DISTINCT ?ct ?reference ?interv1 ?reduction1 ?interv2 ?reduction2
WHERE{
{
?medic1 :hasDrug :Latanoprost. ?medic2 :hasDrug :Timolol.
?interv1 :hasMedication ?medic1. ?interv2 :hasMedication ?medic2.
?arm1 :hasPrimaryOutcome ?outcome1. ?arm2 :hasPrimaryOutcome ?outcome2.
?outcome1 :hasEndPoint ?endpoint1. ?outcome2 :hasEndPoint ?endpoint2.
?endpoint1 :hasEndpointDescription :Diurnal_IOP.
?endpoint2 :hasEndpointDescription :Diurnal_IOP.
?outcome1 :hasResult ?res1. ?outcome2 :hasResult ?res2.
?res1 :hasAbsoluteValue ?result1. ?res2 :hasAbsoluteValue ?result2.
bind(str(?result1) as ?reduction1) bind(str(?result2) as ?reduction2)
?arm1 :hasIntervention ?interv1. ?arm2 :hasIntervention ?interv2.
?ct :hasArm ?arm1. ?ct :hasArm ?arm2.
?pub :describes ?ct. ?pub rdfs:label ?reference.
FILTER (?result1 > ?result2)
}UNION{
?medic1 :hasDrug :Latanoprost. ?medic2 :hasDrug :Timolol.
?interv1 :hasMedication ?medic1. ?interv2 :hasMedication ?medic2.
?arm1 :hasPrimaryOutcome ?outcome1. ?arm2 :hasPrimaryOutcome ?outcome2.
?outcome1 :hasEndPoint ?endpoint1. ?outcome2 :hasEndPoint ?endpoint2.
?endpoint1 :hasEndpointDescription :Diurnal_IOP.
?endpoint2 :hasEndpointDescription :Diurnal_IOP.
?outcome1 :hasResult ?res1. ?outcome2 :hasResult ?res2.
?res1 :hasAbsoluteValue ?result1. ?res2 :hasAbsoluteValue ?result2.
bind(str(?result1) as ?reduction1) bind(str(?result2) as ?reduction2)
?arm1 :hasIntervention ?interv1. ?arm2 :hasIntervention ?interv2.
?ct :hasArm ?arm1. ?ct :hasArm ?arm2.
?pub :describes ?ct. ?pub rdfs:label ?reference.
FILTER (?result1 < ?result2)
}} ORDER BY ?ct
B.2 Query for Retrieving P-values
This query retrieves the statistical significance (p-values) of the diurnal IOP reductions
of the interventions in the case study on glaucoma.
SELECT DISTINCT ?ct ?interv1 ?pvalue1 ?interv2 ?pvalue2
WHERE{
{
?medic1 :hasDrug :Latanoprost. ?medic2 :hasDrug :Timolol.
?interv1 :hasMedication ?medic1. ?interv2 :hasMedication ?medic2.
?arm1 :hasIntervention ?interv1. ?arm2 :hasIntervention ?interv2.
?arm1 :hasPrimaryOutcome ?outcome1. ?arm2 :hasPrimaryOutcome ?outcome2.
?outcome1 :hasEndPoint ?endpoint1. ?outcome2 :hasEndPoint ?endpoint2.
?endpoint1 :hasEndpointDescription :Diurnal_IOP.
?endpoint2 :hasEndpointDescription :Diurnal_IOP.
?outcome1 :hasResult ?res1. ?outcome2 :hasResult ?res2.
?res1 :hasAbsoluteValue ?result1. ?res2 :hasAbsoluteValue ?result2.
?res1 :hasStatisticalMeasure ?st1. ?res2 :hasStatisticalMeasure ?st2.
?st1 :hasPValue ?pvalue1. ?st2 :hasPValue ?pvalue2.
?ct :hasArm ?arm1. ?ct :hasArm ?arm2.
FILTER (?result1 > ?result2)
} UNION{
?medic1 :hasDrug :Latanoprost.
?medic2 :hasDrug :Timolol.
?interv1 :hasMedication ?medic1. ?interv2 :hasMedication ?medic2.
?arm1 :hasIntervention ?interv1. ?arm2 :hasIntervention ?interv2.
?arm1 :hasPrimaryOutcome ?outcome1. ?arm2 :hasPrimaryOutcome ?outcome2.
?outcome1 :hasEndPoint ?endpoint1. ?outcome2 :hasEndPoint ?endpoint2.
?endpoint1 :hasEndpointDescription :Diurnal_IOP.
?endpoint2 :hasEndpointDescription :Diurnal_IOP.
?outcome1 :hasResult ?res1. ?outcome2 :hasResult ?res2.
?res1 :hasAbsoluteValue ?result1. ?res2 :hasAbsoluteValue ?result2.
?res1 :hasStatisticalMeasure ?st1. ?res2 :hasStatisticalMeasure ?st2.
?st1 :hasPValue ?pvalue1. ?st2 :hasPValue ?pvalue2.
?ct :hasArm ?arm1. ?ct :hasArm ?arm2.
FILTER (?result1 < ?result2)
}} ORDER BY ?ct
Appendix C Annotated File
Figure 4 shows an excerpt of an annotated file according to the SANTO’s annotation
schema, which is formed by the comma-separated fields indicated in the first row: An-
notationID is an id number assigned to each annotation, ClassType is the C-TrO class to
which the annotated entity belongs, DocCharOnset and DocCharOffset are the first and
last position of the annotated text (i.e., the annotation span), Text is the annotated text
(i.e., entity), Meta is an optional comment added to the annotation, and Instances are the
instances of the C-TrO classes containing individual annotations as properties. The RDF
file contains the triples formed by the annotated groups which represent domains and
ranges linked by the respective properties.
#AnnotationID,ClassType, DocCharOnset(incl),DocCharOffset(excl),Text,Meta,Instances
1, Journal, 0, 13, "Ophthalmology", "", "<http://ctro/data/Publication_1>
<http://ctro/data/hasJournal > \"Ophthalmology\"."
2, PublicationYear, 16, 20, "1999", "", "<http://ctro/data/Publication_1>
<http://ctro/data/hasPublicationYear> \"1999\"."
3, Title, 46, 149, "A 12-month , randomized , double-masked study comparing
latanoprost with timolol in pigmentary glaucoma", "",
"<http://ctro/data/Publication_1> <http://ctro/data/hasTitle > \ "A 12-month ,
randomized , double-masked study comparing latanoprost with timolol in
pigmentary glaucoma\"."
4, Author, 152, 166, "Mastropasqua L", "", "<http://ctro/data/Publication_1>
<http://ctro/data/hasAuthor > \"Mastropasqua L\"."
5, Author, 175, 186, "Carpineto P", "", "<http://ctro/data/Publication_1>
<http://ctro/data/hasAuthor > \"Carpineto P\"."
6, Author, 189, 202, "Ciancaglini M", "", "<http://ctro/data/Publication_1>
<http://ctro/data/hasAuthor > \"Ciancaglini M\"."
7, Author, 205, 216, "Gallenga PE", "", "<http://ctro/data/Publication_1>
<http://ctro/data/hasAuthor > \"Gallenga PE\"."
RDF File
<http://ctro/data/Publication_1> <http://ctro/data/describes>
<http://ctro/data/ClinicalTrial_1> .
Figure 4. Extract of an annotated file in “annotated format” showing a Publication group (instance of Publi-
cation) and the extract of the corresponding RDF file showing its relationship (describes) with ClinicalTrial 1
(instance of ClinicalTrial).
